A prospective, open-label study to evaluate symptomatic remission in schizophrenia with long acting risperidone microspheres (Risperdal Consta)
Phase of Trial: Phase IV
Latest Information Update: 29 Jan 2009
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutica
- 29 Jan 2009 Actual end date (Apr 2007) added as reported by ClinicalTrials.gov.
- 29 Jan 2009 Planned number of patients changed from 745 to 527 as reported by ClinicalTrials.gov.
- 29 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.